Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
Empowered Patient Podcast
Claim This Podcastby Karen Jagoda
5.0(2 reviews)
2,734 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
78
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality93
Social0
YouTube68
Engagement90
Podcast Overview
Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
Language
🇺🇲
Publishing Since
5/14/2015
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
78
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality93
Social0
YouTube68
Engagement90
8
Excellent Areas
2
Good Performance
9
Growth Opportunities
excellent
Publishing Consistency
Every 2 days
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
poor
Episode Thumbnails
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Empowered Patient Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 8, 2026
Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health TRANSCRIPT
<p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><strong> Harith Rajagopalan</strong>, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification. </span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients." </span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><span style="font-family: Calibri, sans-serif; color: black;"> "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment."</span></span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><span style="font-family: Calibri, sans-serif; color: black;"> "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine."</span></span></p> <p class="MsoNormal" style= "mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal; mso-outline-level: 2;"> <span style= "font-size: 12pt; font-family: Calibri, sans-serif;">#FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy</span></p> <p><strong><span style="font-size: 12pt;"><a title="Fractyl" href= "http://fractyl.com" target="_blank" rel="noopener"><span style= "font-family: Calibri, sans-serif; color: black;">fractyl.com</span></a></span></strong></p> <p><strong><a title="Interview with Fractyl" href= "http://empoweredpatientradio.com/targeting-root-causes-of-obesity-and-metabolic-disease-with-harith-rajagopalan-fractyl-health" target="_blank" rel="noopener"><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Listen to the podcast here</span></a></strong></p> <p><a title="Fractyl" href="http://fractyl.com" target="_blank" rel="noopener"><span style= "font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; color: black; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> <img src="//assets.libsyn.com/show/69801/Fractyl.png" alt="Fractyl" width="278" height="156" /></span></a></p>
July 8, 2026
Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health
<p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><strong> Harith Rajagopalan</strong>, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification. </span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients." </span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><span style="font-family: Calibri, sans-serif; color: black;"> "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment."</span></span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><span style="font-family: Calibri, sans-serif; color: black;"> "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine."</span></span></p> <p class="MsoNormal" style= "mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal; mso-outline-level: 2;"> <span style= "font-size: 12pt; font-family: Calibri, sans-serif;">#FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy</span></p> <p><strong><span style="font-size: 12pt;"><a title="Fractyl" href= "http://fractyl.com" target="_blank" rel="noopener"><span style= "font-family: Calibri, sans-serif; color: black;">fractyl.com</span></a></span></strong></p> <p><strong><a title="Interview with Fractyl Health" href= "http://empoweredpatientradio.com/targeting-root-causes-of-obesity-and-metabolic-disease-with-harith-rajagopalan-fractyl-health-transcript" target="_blank" rel="noopener"><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Download the transcript here</span></a></strong></p> <p><a title="Fractyl" href="http://fractyl.com" target="_blank" rel="noopener"><span style= "font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; color: black; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> <img src="//assets.libsyn.com/show/69801/Fractyl.png" alt="Fractyl" width="278" height="156" /></span></a></p>
July 8, 2026
Using Exosomes-Based Therapy to Restore Function After Traumatic Spinal Cord Injury with Lior Shaltiel NurExone TRANSCRIPT
<p><span style="font-size: 12pt;"><span style= "font-family: Calibri, sans-serif; color: black;"><strong>Lior Shaltiel</strong>, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology</span> <span style= "font-family: Calibri, sans-serif;">aims to stimulate nerve growth by</span> <span style="font-family: Calibri, sans-serif;">targeting a protein that inhibits cell proliferation. Using exosomes, which are secreted by cells, to deliver the drug</span> <span style= "font-family: Calibri, sans-serif;">in a localized manner is possible because of the ability of the exosomes to home in on damaged tissues and cross the blood-brain barrier.</span></span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Lior explains, "At the moment, the medicine can only treat it by treating the symptoms. There are a few attempts to try to regenerate the nerves that are broken and to have the reconnection of the spinal cord injury or any damage in the central nervous system. And this is a huge challenge for medicine, so far not solved. And when we solve it, we prepare to answer and give hope to so many patients, not only in spinal cord injury, but also in other injuries, such as traumatic brain injury, optic nerve, and ophthalmology. So many nerves that we have so far not been able to restore the function after the damage."</span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;"><span style="font-family: Calibri, sans-serif; color: black;"> "So traumatic, meaning we are talking about injury, the acute phase of a disease or illness. In most cases, let's say, spinal cord injury is due to injury, car accidents, or sports accidents. But, for example, ophthalmology, glaucoma, which is a chronic disease, can also cause damage to the optic nerve that cannot be restored. So it can be due to another illness, as a side effect of the illness, or due to injury." </span></span></p> <p><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">"So we discussed the RNA. This is one part of the technology here. Second, the technology of using our natural transmitter in our body, which is how cells communicate with each other, is called exosomes. Exosomes are tiny vesicles secreted from cells with tiny envelopes that a healthy tissue sends to a damaged tissue, a cell that is affected, or a cell that doesn't feel good. And when we understand this mechanism, we can use those exosomes as a drug delivery system."</span></p> <p class="MsoNormal" style= "mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal; mso-outline-level: 2;"> <span style= "font-size: 12pt; font-family: Calibri, sans-serif;">#NurExone #Exosomes #SpinalCordInjury #NeuroRegeneration #PTEN #siRNA #DrugDelivery #Neurology #RegenerativeMedicine #Nanomedicine </span></p> <p><strong><span style="font-size: 12pt;"><a title="NurExone" href= "http://nurexone.com" target="_blank" rel="noopener"><span style= "font-family: Calibri, sans-serif; color: black;">nurexone.com</span></a></span></strong></p> <p><strong><a title="Interview with NurExone" href= "http://empoweredpatientradio.com/using-exosomes-based-therapy-to-restore-function-after-traumatic-spinal-cord-injury-with-lior-shaltiel-nurexone" target="_blank" rel="noopener"><span style= "font-size: 12pt; font-family: Calibri, sans-serif; color: black;">Listen to the podcast here</span></a></strong></p> <p><a title="NurExone" href="http://nurexone.com" target="_blank" rel="noopener"><img src= "//assets.libsyn.com/show/69801/nurexone-20260630-uljzmcy49j.jpeg" alt="NurExone" width="171" height="171" /></a></p>
2,734 total episodes available with 4 transcripts
Recent guests on Empowered Patient Podcast
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Alexander Tsiaras
Guest
Seth Cohen
Guest
Seth Cohen Cedar
Guest
Jim Foote
Guest
Deb Nevins
Guest
Jill Eubank
Guest
Daniel Blumenthal
Guest
Rick Geoffrion
Guest
Loren Larsen
Guest
David Fischel
Guest
Craig Limoli
Guest
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Empowered Patient Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Empowered Patient Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.